Coherus launches Udenyca wearable injector device
LTS Lohmann Therapie-Systeme, a pharmaceutical technology company, announced that its customer, Coherus, has launched its Udenyca on-body injector utilizing the LTS Sorrel wearable drug delivery platform.
Udenyca (pegfilgrastim-cbqv) is a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia. The Udenyca OBI received approval from the Food and Drug Administration in December 2024. The device sets new standards for performance, quality, reliability and patient convenience in wearable injection devices, the company said.
[Read more: Mark Cuban Cost Plus Drug Company partners with Coherus to offer Humira biosimilar]
Coherus and LTS have been working in partnership to receive approval for the delivery of Udenyca OBI. The novel drug delivery device platform will assist Udenyca patients in receiving the drug in the comfort of their home and is intended to lower a patient's risk of infection after they have received chemotherapy.
Bas van Buijtenen, CEO of LTS, said, "This launch completes the market entry of LTS into Biologics, bringing the ease of administration that LTS's solutions are known for to new class of therapies. Our capacity is ready to scale up, providing access to this advantageous solution to all patients swiftly."
[Read more: Sandoz to acquire Cimerli business from Coherus for $170M]
"The approval by the U.S. FDA was a clear vote of confidence and an important milestone for the Sorrel platform. The launch shows our capability to manufacture and delivery according to market needs," said Andrei Yosef, president and general manager of LTS Device Technologies. "Approval and launch will accelerate our other partnered programs running on the same platform, as well as programs with partners looking to obtain market access in the future."